抗体药物N-糖表征及质量研究策略探讨
Discussion on Characterization and Quality Control Strategies of Antibody N-Glycosylation
DOI: 10.12677/PI.2021.103012, PDF,   
作者: 居雪玲：中国药科大学生命科学与技术学院，江苏 南京;上海药明生物技术有限公司，上海；夏晗雪, 周于人, 季昌明, 徐意人*：上海药明生物技术有限公司，上海；邢莹莹*：中国药科大学生命科学与技术学院，江苏 南京
关键词: 抗体药物；糖基化修饰；分析策略；质量研究；Antibody Drugs； Glycosylation； Analytical Strategy； Quality Control
摘要: 糖基化修饰是抗体药物的关键质量属性(Critical Quality Attributes, CQAs)之一。在现代抗体工业中，调节和控制糖基化修饰对抗体的药代动力学(PK)，活性及免疫原性都有着重要影响。作为蛋白质众多翻译后修饰中最为复杂且重要的修饰之一，N-糖的表征和质量控制往往充满挑战。早期研发时，为创新型药物制定高效的N-糖分析策略和为生物类似药制定与原研药的N-糖相似性判定标准是关键的；工业生产时，证明工艺条件变更前后的N-糖质量可比是必要的。本文综述了抗体药物N-糖基化修饰在不同水平上的表征方法，并结合相关法规，对创新型药物和生物类似药在研发阶段和工业生产阶段的N-糖质量研究策略进行了讨论。
Abstract: Glycosylation is one of the critical quality attributes (CQAs) of antibody drugs. In the modern anti-body industry, the regulation and control of glycosylation has avital impact on the pharmacokinetics (PK), potency and immunogenicity. As one of the most complicate and important modifications among all post-translational modifications (PTMs), the characterization and quality control of N-glycans can be very challenging. In the early stage, it is critically important to develop efficient N-glycan analysis strategies for innovative drugs and establish N-glycan similarity criteria for biosimilar; in the late stage, comparability study of N-glycans is necessary when manufacturing process changed. This article reviews the characterization methods of N-glycosylation of antibody drugs at different levels, and discusses the N-glycan research strategies of innovative drugs and biosimilars in the early and late stages in conjunction with relevant regulations.
文章引用：居雪玲, 夏晗雪, 周于人, 季昌明, 邢莹莹, 徐意人. 抗体药物N-糖表征及质量研究策略探讨[J]. 药物资讯, 2021, 10(3): 85-91. https://doi.org/10.12677/PI.2021.103012

参考文献

[1] Kaplon, H., Muralidharan, M., Schneider, Z. and Reichert, J.M. (2020) Antibodies to Watch in 2020. mAbs, 12, Article ID: 1703531. [Google Scholar] [CrossRef] [PubMed]
[2] Kaplon, H. and Reichert, J.M. (2021) Anti-bodies to Watch in 2021. mAbs, 13, Article ID: 1860476. [Google Scholar] [CrossRef] [PubMed]
[3] Lu, R.M., Hwang, Y.C., Liu, I.J., Lee, C.C., Tsai, H.-Z., Li, H.J., et al. (2020) Development of Therapeutic Antibodies for the Treatment of Diseases. Journal of Biomedical Science, 27, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[4] Mimura, Y., Ashton, P.R., Takahashi, N., Harvey, D.J. and Jef-feris, R. (2007) Contrasting Glycosylation Profiles between Fab and Fc of a Human IgG Protein Studied by Electrospray Ionization Mass Spectrometry. Journal of Immunological Methods, 326, 116-126. [Google Scholar] [CrossRef] [PubMed]
[5] Zhou, Q. and Qiu, H. (2019) The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins. Journal of Pharmaceutical Sciences, 108, 1366-1377. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, Z., Zhu, J. and Lu, H. (2020) Antibody Glycosylation: Impact on Antibody Drug Characteristics and Quality Control. Applied Microbiology and Biotechnology, 104, 1905-1914. [Google Scholar] [CrossRef] [PubMed]
[7] Lee, S.J., Evers, S., Roeder, D., Parlow, A.F., Risteli, J., Risteli, L., et al. (2002) Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis. Science, 295, 1898-1901. [Google Scholar] [CrossRef] [PubMed]
[8] Goetze, A.M., Liu, Y.D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P.V., et al. (2011) High-Mannose Glycans on the Fc Region of Therapeutic IgG Antibodies Increase Serum Clearance in Humans. Glycobiology, 21, 949-959. [Google Scholar] [CrossRef] [PubMed]
[9] Treffers, L.W., Van Houdt, M., Bruggeman, C.W., Heineke, M.H., Zhao, X.W., van der Heijden, J., et al. (2019) FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils. Frontiers in Immunology, 10, Article No. 3124. [Google Scholar] [CrossRef] [PubMed]
[10] Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., et al. (2012) Production, Characterization and Pharmacokinetic Properties of Antibodies with N-Linked Mannose-5 Gly-cans. mAbs, 4, 475-487. [Google Scholar] [CrossRef] [PubMed]
[11] Quast, I., Keller, C.W., Maurer, M.A., Giddens, J.P., Tackenberg, B., Wang, L.-X., et al. (2015) Sialylation of IgG Fc Domain Impairs Complement-Dependent Cytotoxicity. Journal of Clin-ical Investigation, 125, 4160-4170. [Google Scholar] [CrossRef] 
[12] Luo, C., Chen, S., Xu, N., Wang, C., Sai, W., Zhao, W., et al. (2017) Gly-coengineering of Pertuzumab and Its Impact on the Pharmacokinetic/Pharmacodynamic Properties. Scientific Reports, 7, Article No. 46347. [Google Scholar] [CrossRef] [PubMed]
[13] Maeda, E., Kita, S., Kinoshita, M., Urakami, K., Hayakawa, T. and Kakehi, K. (2012) Analysis of Nonhuman N-Glycans as the Minor Constituents in Recombinant Monoclonal Antibody Pharma-ceuticals. Analytical Chemistry, 84, 2373-2379. [Google Scholar] [CrossRef] [PubMed]
[14] Bobaly, B., D’Atri, V., Goyon, A., Colas, O., Beck, A., Fekete, S., et al. (2017) Protocols for the Analytical Characterization of Therapeutic Monoclonal Antibodies. II—Enzymatic and Chemical Sample Preparation. Journal of Chromatography B, 1060, 325-335. [Google Scholar] [CrossRef] [PubMed]
[15] Yang, X. and Bartlett, M.G. (2019) Glycan Analysis for Protein Therapeutics. Journal of Chromatography B, 1120, 29-40. [Google Scholar] [CrossRef] [PubMed]
[16] 徐云霞. N-糖基化修饰对人源化IgG抗体药物生产细胞株筛选的重要性[D]: [硕士学位论文]. 南京: 南京大学, 2013.
[17] Dillon, T.M., Bondarenko, P.V., Rehder, D.S., Pipes, G.D., Kleemann, G.R. and Speed Ricci, M. (2006) Optimization of a Reversed-Phase High-Performance Liquid Chromatography/Mass Spectrometry Method for Characterizing Recombinant Antibody Heterogeneity and Stability. Journal of Chromatography A, 1120, 112-120. [Google Scholar] [CrossRef] [PubMed]
[18] Yan, B., Valliere-Douglass, J., Brady, L., Steen, S., Han, M., Pace, D., et al. (2007) Analysis of Post-Translational Modifications in Recombinant Monoclonal Antibody IgG1 by Re-versed-Phase Liquid Chromatography/Mass Spectrometry. Journal of Chromatography A, 1164, 153-161. [Google Scholar] [CrossRef] [PubMed]
[19] Strupat, K. (2005) Molecular Weight Determination of Peptides and Proteins by ESI and MALDI. Methods in Enzymology, 405, 1-36. [Google Scholar] [CrossRef] 
[20] An, Y., Zhang, Y., Mueller, H.M., Shameem, M. and Chen, X. (2014) A New Tool for Monoclonal Antibody Analysis. mAbs, 6, 879-893. [Google Scholar] [CrossRef] [PubMed]
[21] Sjögren, J., Olsson, F. and Beck, A. (2016) Rapid and Improved Char-acterization of Therapeutic Antibodies and Antibody Related Products Using IdeS Digestion and Subunit Analysis. The Analyst, 141, 3114-3125. [Google Scholar] [CrossRef] 
[22] Wang, W., Meeler, A.R., Bergerud, L.T., Hesselberg, M., Byrne, M. and Wu, Z. (2012) Quantification and Characterization of Antibody Deamidation by Peptide Mapping with Mass Spec-trometry. International Journal of Mass Spectrometry, 312, 107-113. [Google Scholar] [CrossRef] 
[23] Dick, L.W., Mahon, D., Qiu, D. and Cheng, K.-C. (2009) Peptide Mapping of Therapeutic Monoclonal Antibodies: Improvements for Increased Speed and Fewer Artifacts. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 877, 230-236. [Google Scholar] [CrossRef] [PubMed]
[24] Riley, N.M., Bertozzi, C.R. and Pitteri, S.J. (2020) A Prag-matic Guide to Enrichment Strategies for Mass Spectrometry-Based Glycoproteomics. Molecular & Cellular Proteomics, 20, Article ID: 100029. [Google Scholar] [CrossRef] 
[25] Guo Y. (2015) Recent Progress in the Fundamental Understanding of Hydrophilic Interaction Chromatography (HILIC). The Analyst, 140, 6452-6466. [Google Scholar] [CrossRef] 
[26] European Medicines Agency (1999) Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Topic Q6B, European Medicines Agency, Lon-don.
[27] European Medicines Agency (2016) Guideline on Development, Production, Characterization and Specifica-tion for Monoclonal Antibodies and Related Products, European Medicines Agency, London.
[28] European Medicines Agency (2004) Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Pro-cess. ICH Topic Q5E, European Medicines Agency, London.
[29] European Medicines Agency (2012) ICH Guideline Q11 on Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). European Medicines Agency, London.
[30] Food and Drug Administration (1997) Points to Consider in the Manufac-ture and Testing of Therapeutic Products for Human Use. U.S. Food and Drug Administration, Rockville.
[31] 国家药品监督管理局. 生物类似药相似性评价和适应症外推技术指导原则[S]. 北京: 国家药品监督管理局, 2021.
[32] Le, H., Vishwanathan, N., Jacob, N.M., Gadgil, M. and Hu, W.-S. (2015) Cell Line Development for Bi-omanufacturing Processes: Recent Advances and an Outlook. Biotechnology Letters, 37, 1553-1564. [Google Scholar] [CrossRef] [PubMed]
[33] Li, F., Vijayasankaran, N., Shen, A.Y.J., Kiss, R. and Amanullah, A. (2010) Cell Culture Processes for Monoclonal Antibody Production. mAbs, 2, 466-479. [Google Scholar] [CrossRef] [PubMed]
[34] Gandhi, S., Ren, D., Xiao, G., Bondarenko, P., Sloey, C., Speed Ric-ci, M., et al. (2012) Elucidation of Degradants in Acidic Peak of Cation Exchange Chromatography in an IgG1 Mono-clonal Antibody Formed on Long-Term Storage in a Liquid Formulation. Pharmaceutical Research, 29, 209-224. [Google Scholar] [CrossRef] [PubMed]
[35] 张忠兵, 韦薇, 罗建辉. 生物类似药糖基化相似性评价中的审评思考[J]. 中国新药杂志, 2020, 29(21): 2476-2480.
[36] Kim, S., Song, J., Park, S., Ham, S., Paek, K., Kang, M., et al. (2017) Drifts in ADCC-Related Quality Attributes of Herceptin®: Impact on Development of a Trastuzumab Bio-similar. mAbs, 9, 704-714. [Google Scholar] [CrossRef] [PubMed]
[37] Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H. and Grau, R. (2011) Acceptable Changes in Quality Attributes of Glycosylated Biopharmaceuticals. Nature Biotechnolo-gy, 29, 310-312. [Google Scholar] [CrossRef] [PubMed]
[38] 徐刚领, 韦薇, 罗建辉, 白玉. 单抗药物N-糖基化修饰对结构功能影响及相关药学问题考量[J]. 药学学报, 2020, 55(6): 1345-1350.
[39] 刘伯宁, 徐刚领, 罗建辉. 关于我国单抗药物上市阶段药学评价的思考[J]. 药学学报, 2019, 54(11): 2126-2134.
[40] Ma, B., Guan, X., Li, Y., Shang, S., Li, J. and Tan, Z. (2020) Protein Glycoengineering: An Approach for Improving Protein Properties. Frontiers in Chemistry, 8, Article No. 622. [Google Scholar] [CrossRef] [PubMed]
[41] Jefferis, R. (2016) Gly-co-Engineering of Human IgG-Fc to Modulate Biologic Activities. Current Pharmaceutical Biotechnology, 17, 1333-1347. [Google Scholar] [CrossRef] [PubMed]
[42] Beck, A. and Reichert, J.M. (2012) Mar-keting Approval of Mogamulizumab: A Triumph for Glyco-Engineering. mAbs, 4, 419-425. [Google Scholar] [CrossRef] [PubMed]